摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-Fluoro-6-hydroxyphenyl)-2-methylpropan-1-one | 881190-63-2

中文名称
——
中文别名
——
英文名称
1-(2-Fluoro-6-hydroxyphenyl)-2-methylpropan-1-one
英文别名
1-(2-Fluoro-6-hydroxyphenyl)-2-methyl-1-propanone
1-(2-Fluoro-6-hydroxyphenyl)-2-methylpropan-1-one化学式
CAS
881190-63-2
化学式
C10H11FO2
mdl
——
分子量
182.195
InChiKey
QQGPNXZHTPJDKH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Cyclic amine derivative or salt thereof
    申请人:Hayashibe Satoshi
    公开号:US20070197594A1
    公开(公告)日:2007-08-23
    Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro- 1 H-cyclopenta[1]naphthalene) via X 1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.
    提供的化合物是NMDA受体拮抗剂,具有广泛的安全边界,并可用作治疗或预防阿尔茨海默病、脑血管性痴呆、帕金森病、缺血性卒中、疼痛等药物。具体提供的是胺衍生物或其盐,其特点在于其中含有胺基结构A,通过X1(键或低碳烷基)与2-或3-环状紧缩环(例如茚烷、四氢萘酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-茚并[4,5-b]呋喃、2,3-二氢-1H-环戊[1]萘烷)结合;以及含有它作为有效成分的NMDA受体拮抗剂。
  • HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
    申请人:Rodgers James D.
    公开号:US20110059951A1
    公开(公告)日:2011-03-10
    The present invention provides heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    本发明提供了吡唑-4-基-吡咯[2,3-d]嘧啶的杂环衍生物,以及它们的组合物和使用方法,可以调节Janus激酶(JAKs)的活性,并且在治疗与JAKs活性相关的疾病方面有用,例如炎症性疾病、自身免疫性疾病、癌症和其他疾病。
  • CYCLIC AMINE DERIVATIVE OR SALT THEREOF
    申请人:Astellas Pharma Inc.
    公开号:EP1795524A1
    公开(公告)日:2007-06-13
    Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro-1H-cyclopenta[1]naphthalene) via X1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.
    本发明提供的化合物是一种具有广泛安全范围的 NMDA 拮抗剂,可作为阿尔茨海默病、脑血管痴呆症、帕金森病、缺血性脑中风、疼痛等的治疗剂或预防剂。具体而言,提供了一种胺衍生物或其盐,其特征在于其中的含胺结构 A 与 2-或 3-环缩合环(如茚满、四烯酮、4-环缩合环、5-环缩合环、6-环缩合环、7-环缩合环、8-环缩合环、9-环缩合环)结合、茚、四酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-茚并[4,5-b]呋喃、2,3-二氢-1H-环戊并[1]萘)通过 X1(键或低级亚烷基)结合;以及含有它作为其活性成分的 NMDA 拮抗剂。
  • SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF
    申请人:Memorial Sloan-Kettering Cancer Center
    公开号:US20220162209A1
    公开(公告)日:2022-05-26
    Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts or tautomers thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g., Mycobacterium infection (e.g., tuberculosis)). (I)
  • US9249145B2
    申请人:——
    公开号:US9249145B2
    公开(公告)日:2016-02-02
查看更多